J&J'S PLANNED ACQUISITION OF MENLO CARE PAVES WAY FOR VERSACATH
This article was originally published in The Gray Sheet
Executive Summary
J&J'S PLANNED ACQUISITION OF MENLO CARE PAVES WAY FOR VERSACATH introduction, nearly three years after the Menlo Care acute central venous catheter system received FDA 510(k) marketing clearance. Cleared in 1992, Versacath combines a Mainline single- lumen percutaneous introducer sheath and a Selectalumen single- or double-lumen inner catheter that can be inserted into the Mainline. The design allows Versacath to become a multi-lumen catheter for the administration of complex drug therapies.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.